
Baricitinib tablets
Form: Tablets
Strength: 2 mg, 4 mg
Reference Brands: Olumiant®(EU & US- Emergency Use Authorization (EUA)
Category: Arthritis
Baricitinib tablets are approved in the EU and US for moderate to severe rheumatoid arthritis. In the EU, Eli Lilly’s Olumiant is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical trial data and biosimilarity assessments. Both regions require detailed dossiers for approval and continuous pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for baricitinib tablets, ensuring adherence to European and American standards for safe, effective management of autoimmune diseases, helping you navigate complex regulatory landscapes seamlessly.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Pegloticase injecatble
Strength: 8 mg/1.2 mL vial
Form: Injectable (IV solution)
Reference Brands: Krystexxa (US)
View Details Get EnquiryColchicine tablest
Strength: 0.6 mg
Form: Tablet
Reference Brands: Colcrys(US)
View Details Get EnquiryFebuxostat tablets
Strength: 40 mg, 80 mg
Form: Oral Tablets
Reference Brands: Uloric(EU & US)
View Details Get EnquiryAllopurinol tablets
Strength: 100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View Details Get Enquiry